Although limited data suggest that females as well as Asian and Pacific Island patients may have higher exposure to efavirenz, they do not appear to be less tolerant of efavirenz.
Piiratud andmetel on naistel ning Aasia ja Vaikse Ookeani regiooni patsientidel efavirensi toime tugevam, kuid nad taluvad ravimit sarnaselt teistele.